Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
09/2003
09/25/2003WO2003077950A1 Enhanced feeding and growth rates of aquatic animals fed an astaxanthin product derived from marigold extract
09/25/2003WO2003077943A2 Method for the production of a pharmaceutical preparation by adsorption in a poorly soluble aluminum compound
09/25/2003WO2003077940A1 Chemical igf-i composition for the treatment and prevention of neurodegenerative diseases
09/25/2003WO2003077937A1 Pharmaceutical compositions comprising mannose binding lectin
09/25/2003WO2003077928A1 Peptide analogues and uses thereof
09/25/2003WO2003077923A1 Progesterone oral drug delivery system
09/25/2003WO2003077922A1 Composition in an aqueous gel state, method for the production and use thereof in the production of a medicament, in particular an antiherpetic medicament
09/25/2003WO2003077920A1 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo’1,5-bipyridazine in nanoparticulate form
09/25/2003WO2003077890A1 Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion.
09/25/2003WO2003077888A2 Compressed tablets comprising microcapsules with modified release
09/25/2003WO2003077885A2 Free-base formulations of local anesthetics
09/25/2003WO2003077884A1 A topical synergistic microbicide
09/25/2003WO2003077883A2 Composition and utilization thereof for forming a protective film on nasal mucous membranes
09/25/2003WO2003077882A2 Preparation of sterile stabilized nanodispersions
09/25/2003WO2003077867A2 Naltrexone hydrochloride compositions
09/25/2003WO2003077865A2 Methods and compositions for directing cells to target organs
09/25/2003WO2003077864A2 Methods and compositions for directing cells to target organs
09/25/2003WO2003077861A2 Water-based delivery systems
09/25/2003WO2003077842A2 Palatable oral suspension and method
09/25/2003WO2003077836A2 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
09/25/2003WO2003077834A2 Central airway administration for systemic delivery of therapeutics
09/25/2003WO2003077811A1 Pharmaceutically active compounds containing phosphorous defficient oil
09/25/2003WO2003077723A2 Methods and devices for detection and therapy of atheromatous plaque
09/25/2003WO2003077668A1 A low fat cocoa extract
09/25/2003WO2003077657A1 Choline-silicic acid complex with osmolytes and divalent trace elements
09/25/2003WO2003070738A3 Topiramate salts and compositions comprising and methods of making and using the same
09/25/2003WO2003061568A3 Methods and therapeutic compositions in the treatment of advanced cancer
09/25/2003WO2003051399A3 Use of substances with an increased molecular weight in tumour therapy
09/25/2003WO2003047552A3 Pharmaceutical composition comprising a 5ht1 receptor agonist
09/25/2003WO2003047494A3 Reverse micelle compositions and uses thereof
09/25/2003WO2003039472A3 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
09/25/2003WO2003032947A3 A method for preparing liposome formulations with a predefined release profile
09/25/2003WO2003022208A3 Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
09/25/2003WO2003020219A3 Aerosolized decongestants for the treatment of sinusitis
09/25/2003WO2003018064A3 Lipophilic drug compositions
09/25/2003WO2003015690A3 Method for treating primary insomnia
09/25/2003WO2003011249A3 Ophthalmic composition containing n-acetylcysteine for the treat ment of dry-eye syndrome
09/25/2003WO2003008454A3 Glycoprotein vi fusion proteins
09/25/2003WO2003006993A3 Gel compositions
09/25/2003WO2002100436A3 Ophthalmic once-a-day composition
09/25/2003WO2002100412A3 Stabilized dispersion of phytosterol in oil
09/25/2003WO2002098339A3 Zinc containing compositions for anti-viral use
09/25/2003WO2002085300A3 Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts
09/25/2003WO2002064634A3 Human monoclonal antibodies to fc alpha receptor (cd89)
09/25/2003WO2002055736A3 Antisense imaging of gene expression of the brain in vivo
09/25/2003WO2002055061A3 Method of producing porous tablets with improved dissolution properties
09/25/2003WO2002046419A3 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
09/25/2003WO2002036161A3 Novel targeted compositions for diagnostic and therapeutic use
09/25/2003WO2002017855A3 Process for preparing pharmaceutical compositions for use with soft gelatin formulations
09/25/2003WO2002014361A3 NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER
09/25/2003US20030181689 Percarboxylated polysaccharides, and a process for their preparation
09/25/2003US20030181662 Human procalcitonin and the preparation and use thereof
09/25/2003US20030181602 Mixtures of glycerides, polyethers, fatty alcohols, waxes and/or ethylene oxide fatty alcohol adducts, used to form (micro)emulsions, having storage stability
09/25/2003US20030181530 Soluble compositions of triphenylethylene antiestrogens
09/25/2003US20030181527 Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone
09/25/2003US20030181526 Administering formulation comprising urea and dermatologically acceptable excipients for therapy of onychomycosis infection of nail area
09/25/2003US20030181525 Method of treating onychomycosis
09/25/2003US20030181521 Use of vegetable butter-based cetyl myristoleate for treating osteoarthritis and other musculoskeletal disease conditions and injuries
09/25/2003US20030181515 Administering to a subject in need of pain relief a medicinal ointment comprising an active kavalactone selected from the group consisting of dihydrokawain, dihydromethysticin, kawain and medicinally acceptable carrier
09/25/2003US20030181512 For therapy and prophylaxis of obesity and hyperlipidemia; side effect reduction
09/25/2003US20030181501 Therapy and prophylaxis of cyclooxygenase-2 mediated conditions and disorders
09/25/2003US20030181432 Particularly particles of therapeutically useful or carrier substances of a size suitable for inhalation therapy
09/25/2003US20030181430 Novel topical oestroprogestational compositions with a systemic effect
09/25/2003US20030181418 Pharmaceutical composition
09/25/2003US20030181415 Use of these compounds for prevention and inhibition of malignant epithelial lesions associated with papilloma virus, such as cervical cancer
09/25/2003US20030181411 Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer
09/25/2003US20030181390 Sustained release of aminobutyric acid using prodrugs such as L-1-naphthylalanine-gabapentin, administered for prophylaxis of nervous system disorders, as anxiolytics, antidepressants or antiinflammatory agents; drug delivery
09/25/2003US20030181389 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
09/25/2003US20030181387 Intranasal administration of polypeptides in powdered form
09/25/2003US20030181371 Compositions and methods of using collajolie
09/25/2003US20030181367 Membrane translocation peptides, compositions comprising them, chimeric molecules comprising them, and methods of using them to achieve transmembrane transport of various agents.
09/25/2003US20030181361 Sustained-release pharmaceutical formulations of therapeutic proteins containing carboxymethyl ether cellulose polymer and methods of manufacture and use thereof.
09/25/2003US20030181359 Tripeptide prodrug compounds
09/25/2003US20030180924 Formulation of certain pyrazolo [3,4,-d] pyrimidines as kinase modulators
09/25/2003US20030180755 Pharmaceutical compositions in particulate form
09/25/2003US20030180491 Administering therapeutic dosage to mammals; immobilization
09/25/2003US20030180386 Aqueous metal bicarbonate solution and method of use
09/25/2003US20030180382 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
09/25/2003US20030180379 Microbiocides; anticancer agents; bactericides; antiinflammatory agents; fungicides; viricides
09/25/2003US20030180378 Dry powders of metal-containing compounds
09/25/2003US20030180376 Porous beta-tricalcium phosphate granules and methods for producing same
09/25/2003US20030180369 Microcapsule powder
09/25/2003US20030180366 Bioadhesive drug delivery system
09/25/2003US20030180365 Preparation containing an oxygen carrier for regeneration of the skin in the case of oxygen deficiency
09/25/2003US20030180364 Catheter injectable depot compositions and uses thereof
09/25/2003US20030180363 Biodegradation polymer; liquid phase polyoxyethylene glycol
09/25/2003US20030180362 Multi-stage oral drug controlled-release system
09/25/2003US20030180360 Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2 (11),3,5,7,9-pentaene
09/25/2003US20030180359 Controlled release
09/25/2003US20030180357 Core with coating; water soluble dye in matrix as core; gellan gum coatings; easier detection of tablet
09/25/2003US20030180350 Combination compositions
09/25/2003US20030180335 Moisturizers; transdermal absorption; ethylene oxide-propylene oxide adduct
09/25/2003US20030180332 Novel pharmaceutical composition
09/25/2003US20030180295 Angiocidin: a Cys-Ser-Val-Thr-Cys-Gly specific tumor cell adhesion receptor
09/25/2003US20030180289 Inhibition of secretion from non-neuronal cells
09/25/2003US20030180287 Polypeptide formulation
09/25/2003US20030180285 Treatment of fungal infections with polyene or beta glucan synthase inhibitor anti-fungals combined with anti hsp90 antibodies
09/25/2003US20030180281 Preparations for topical skin use and treatment
09/25/2003US20030180261 Vaccines; cancer therapy; immobilization of virus; supplying tumor
09/25/2003US20030180253 Stabilized liquid polypeptide-containing pharmaceutical compositions
1 ... 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 ... 1712